A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer
Authors
Keywords
-
Journal
CANCER
Volume 119, Issue 15, Pages 2692-2700
Publisher
Wiley
Online
2013-05-30
DOI
10.1002/cncr.28117
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Radiotherapy Combined with Gemcitabine and Oxaliplatin in Pancreatic Cancer Cells
- (2014) Meredith A. Morgan et al. Translational Oncology
- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators
- (2012) Matthew H. G. Katz et al. CANCER
- A Phase I/II Trial of Intensity Modulated Radiation (IMRT) Dose Escalation With Concurrent Fixed-dose Rate Gemcitabine (FDR-G) in Patients With Unresectable Pancreatic Cancer
- (2012) Edgar Ben-Josef et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Preoperative Capecitabine and Concurrent Radiation for Borderline Resectable Pancreatic Cancer
- (2011) Jayme B. Stokes et al. ANNALS OF SURGICAL ONCOLOGY
- Downstaging Chemotherapy and Alteration in the Classic Computed Tomography/Magnetic Resonance Imaging Signs of Vascular Involvement in Patients With Pancreaticobiliary Malignant Tumors
- (2011) Timothy R. Donahue ARCHIVES OF SURGERY
- Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
- (2011) Patrick J. Loehrer et al. JOURNAL OF CLINICAL ONCOLOGY
- A Systematic Review and Meta-analysis of Survival and Surgical Outcomes Following Neoadjuvant Chemoradiotherapy for Pancreatic Cancer
- (2011) Jerome Martin Laurence et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Neoadjuvant GTX Chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer
- (2011) Manish Patel et al. JOURNAL OF SURGICAL ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant therapy in pancreatic adenocarcinoma: A meta-analysis of phase II trials
- (2011) M. Mura Assifi et al. SURGERY
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
- (2010) John P. Neoptolemos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement
- (2009) Mark P. Callery et al. ANNALS OF SURGICAL ONCOLOGY
- Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma
- (2008) William F. Regine et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head
- (2008) Gauri R. Varadhachary et al. JOURNAL OF CLINICAL ONCOLOGY
- Full-Dose Gemcitabine With Concurrent Radiation Therapy in Patients With Nonmetastatic Pancreatic Cancer: A Multicenter Phase II Trial
- (2008) William Small et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head
- (2008) Douglas B. Evans et al. JOURNAL OF CLINICAL ONCOLOGY
- Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease
- (2008) Matthew H.G. Katz et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started